{"id":139207,"date":"2023-01-25T10:40:00","date_gmt":"2023-01-25T15:40:00","guid":{"rendered":"https:\/\/44.250.171.167\/?p=139207"},"modified":"2023-01-25T10:40:02","modified_gmt":"2023-01-25T15:40:02","slug":"infographic-cipla-ltd-nse-cipla-q3-fy23-results-total-income-falls-0-45-qoq","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/infographic-cipla-ltd-nse-cipla-q3-fy23-results-total-income-falls-0-45-qoq\/","title":{"rendered":"Infographic Cipla Ltd.(NSE: CIPLA) | Q3 FY23 Results | Total Income falls -0.45% qoq"},"content":{"rendered":"\n

Cipla Limited (NSE: CIPLA)<\/a> is an Indian multinational pharmaceutical and biopharmaceutical company. Founded in 1935, Cipla primarily develops and sells generic and over-the-counter drugs, active pharmaceutical ingredients, and biopharmaceuticals. The company has operations in over 80 countries, with a focus on the developing world. Cipla is known for its affordable and accessible medicines, particularly in the areas of HIV\/AIDS, respiratory, and cardiovascular disease. Cipla has also invested in research and development to develop new drugs and expand its product portfolio.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

The company’s revenue from operations for the quarter ended December 31st, 2022 was Rs. 5,730.08 crores from the sale of products and Rs. 80.01 crores from other operating revenue, for a total of Rs. 5,810.09 crores. For the nine months ended December 31st, 2022, the revenue from operations was Rs. 16,807.23 crores from the sale of products and Rs. 206.59 crores from other operating revenue, for a total of Rs. 17,013.82 crores. The company’s total income was Rs. 5,924.53 crores, which includes Rs. 114.44 crores from other income. For the nine months ended December 31st, 2022, the total income was Rs. 17,354.64 crores, which includes Rs. 340.82 crores from other income.<\/p>\n\n\n\n

Cipla’s expenses for the quarter ended December 31st, 2022 were Rs. 4,706.47 crores, which includes Rs. 1,299.04 crores for cost of materials consumed, Rs. 948.69 crores for employee benefits expense, and Rs. 272.11 crores for depreciation, impairment, and amortisation expense. For the nine months ended December 31st, 2022, the expenses were Rs. 14,061.66 crores.<\/p>\n\n\n\n

The company’s profit before exceptional items and tax for the quarter ended December 31st, 2022 was Rs. 1,218.06 crores, and for the nine months ended December 31st, 2022 was Rs. 3,292.98 crores. The net profit after tax before share of associates for the quarter ended December 31st, 2022 was Rs. 808.05 crores, and for the nine months ended December 31st, 2022 was Rs. 2,312.37 crores. The net profit for the period\/year was Rs. 807.83 crores for the quarter ended December 31st, 2022, and Rs. 2,311.38 crores for the nine months ended December 31st, 2022.<\/p>\n\n\n\n

Overall, it seems that Cipla has performed well in the quarter and nine months ended December 31st, 2022, with revenue and income growing, and expenses remaining relatively stable. The company’s profit before and after tax has also increased during this period.<\/p>\n","protected":false},"excerpt":{"rendered":"

Cipla Limited (NSE: CIPLA) is an Indian multinational pharmaceutical and biopharmaceutical company. Founded in 1935, Cipla primarily develops and sells generic and over-the-counter drugs, active pharmaceutical ingredients, and biopharmaceuticals. The company has operations in over 80 countries, with a focus on the developing world. Cipla is known for its affordable and accessible medicines, particularly in […]<\/p>\n","protected":false},"author":1932,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,1941,392,5,6350],"tags":[1408,1115],"class_list":["post-139207","post","type-post","status-publish","format-standard","hentry","category-infographics","category-stock-analysis","category-earnings","category-latest","category-trending-stocks","tag-pharma-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":126049,"url":"https:\/\/alphastreet.com\/india\/infographic-how-cipla-performed-in-q2-2022\/","url_meta":{"origin":139207,"position":0},"title":"Infographic: How Cipla performed in Q2 2022","author":"Nishad","date":"December 6, 2021","format":false,"excerpt":"Cipla Limited(NSE: CIPLA) posted its second-quarter 2022 results. The company posted consolidated revenue of \u20b95,580 crores with a growth of 9% year on year. Cipla had a net profit of \u20b9709 crores or \u20b98.80 per share compared to \u20b9659 crores or \u20b98.24 per share in the same quarter of the\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/CiplaQ222.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/CiplaQ222.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/CiplaQ222.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/CiplaQ222.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/CiplaQ222.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":154517,"url":"https:\/\/alphastreet.com\/india\/ruling-the-therapeutic-medical-segment-ft-cipla\/","url_meta":{"origin":139207,"position":1},"title":"Ruling the Therapeutic Medical Segment Ft Cipla","author":"Chirag Gupta","date":"September 1, 2023","format":false,"excerpt":"Our One-India business continued the double-digit trajectory growing at 12% during the quarter led by branded prescription with sustained growth across chronic therapies. Our continued focus on differentiated portfolio has strengthened our US business which once again posted highest ever quarterly revenue at $ 222 Mn. South Africa Private Market\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":125206,"url":"https:\/\/alphastreet.com\/india\/how-did-cipla-perform-in-q2-2022\/","url_meta":{"origin":139207,"position":2},"title":"How Cipla performed in Q2 2022","author":"Nishadkishore","date":"October 26, 2021","format":false,"excerpt":"The pharma giant Cipla (NSE: CIPL) reported its second-quarter 20223 earnings results on Tuesday after market hours. The total revenue increased by 10.3% to \u20b95,486 crores compared to \u20b94,972 crores in the previous year of the same quarter. The company had a total net profit of \u20b9711 crores or \u20b98.80\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":168350,"url":"https:\/\/alphastreet.com\/india\/cipla-ltd-q4fy25-30-rise-in-profits\/","url_meta":{"origin":139207,"position":3},"title":"Cipla Ltd Q4FY25; 30% rise in Profits","author":"Divyansh_Kasana","date":"May 13, 2025","format":false,"excerpt":"\u00a0 Company Overview: Cipla is engaged in the Business of Pharmaceuticals. Cipla has a diversified product portfolio of 1,500+ products in 50+ dosage forms and 65 therapeutic categories. Financial Results: Cipla reported Total revenue for Q4FY25 of \u20b9 7,019 Crore up from \u20b914,932 Crore in Q4FY24, a rise of 9%\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/01fc69a0-257a-4808-8d8c-e6ccf6191eb7.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/01fc69a0-257a-4808-8d8c-e6ccf6191eb7.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/01fc69a0-257a-4808-8d8c-e6ccf6191eb7.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/01fc69a0-257a-4808-8d8c-e6ccf6191eb7.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/01fc69a0-257a-4808-8d8c-e6ccf6191eb7.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/01fc69a0-257a-4808-8d8c-e6ccf6191eb7.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":131066,"url":"https:\/\/alphastreet.com\/india\/cipla-q4-fy2022-research-summary\/","url_meta":{"origin":139207,"position":4},"title":"Cipla Q4 FY2022 Research Summary","author":"sreerupa","date":"July 11, 2022","format":false,"excerpt":"Cipla is an Indian multinational pharmaceutical company. The company was incorporated in the year 1935. The founder is Khwaja Abdul Hamied. Cipla has its headquarters in Mumbai. The company has extended its business worldwide.\u00a0 The presence of this company is marked in Australia, Europe, Kenya, Malaysia, Morocco, Nepal, South Africa,\u2026","rel":"","context":"In "Research Summary"","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"Research Summary","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":167458,"url":"https:\/\/alphastreet.com\/india\/cipla-ltd-q3fy25-47-rise-in-profits\/","url_meta":{"origin":139207,"position":5},"title":"Cipla Ltd Q3FY25; 47% rise in Profits","author":"Divyansh_Kasana","date":"March 19, 2025","format":false,"excerpt":"Cipla is engaged in the Business of Pharmaceuticals.(Source : 202003 Annual Report Page No:157) Financial Results: Cipla Ltd reported Revenues for Q3FY25 of \u20b97,073.00 Crores up from \u20b96,604.00 Crore year on year, a rise of 7.1%. Total Expenses for Q3FY25 of \u20b95,379.00 Crores up from \u20b95,119.00 Crores year on year,\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/U-10.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/U-10.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/U-10.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/U-10.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/U-10.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/U-10.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/139207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=139207"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/139207\/revisions"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=139207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=139207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=139207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}